VIVUS Inc. (VVUS)

3.86
NASDAQ : Health Technology
Prev Close 3.90
Day Low/High 3.83 / 3.99
52 Wk Low/High 2.15 / 9.88
Avg Volume 61.60K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 41.48M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
VIVUS Announces Study Results Showing STENDRA (Avanafil) Is Effective For Sexual Activity Within 15 Minutes In Men With Erectile Dysfunction (ED)

VIVUS Announces Study Results Showing STENDRA (Avanafil) Is Effective For Sexual Activity Within 15 Minutes In Men With Erectile Dysfunction (ED)

Data From Successful Placebo-Controlled Study to be Submitted to Regulatory Authorities to Support STENDRA Label Amendment for 15-Minute Efficacy Claim

VIVUS Posts Investor Presentation

VIVUS Posts Investor Presentation

Open Letter To Vivus Employees Released By First Manhattan Co.

Open Letter To Vivus Employees Released By First Manhattan Co.

First Manhattan Co., the beneficial owner of approximately 9.

Bullish Two Hundred Day Moving Average Cross - VVUS

Bullish Two Hundred Day Moving Average Cross - VVUS

In trading on Thursday, shares of Vivus, Inc. crossed above their 200 day moving average of $14.90, changing hands as high as $15.04 per share.

4 Stocks Spiking on Big Volume

4 Stocks Spiking on Big Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.

New Guidelines From American Association Of Clinical Endocrinologists Recommend Medical Treatment Of Obesity

New Guidelines From American Association Of Clinical Endocrinologists Recommend Medical Treatment Of Obesity

First Guidelines to Incorporate Anti-Obesity Medications as Recommended Treatment for Cardiometabolic Diseases

FDA Loosens Restrictions on Vivus Weight-Loss Pill

FDA Loosens Restrictions on Vivus Weight-Loss Pill

Vivus' Qsymia will now be available at retail pharmacies.

Large Vivus Shareholder Seeks More Change

Large Vivus Shareholder Seeks More Change

A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.

Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch

Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch

The DEA is taking its sweet time determining the abuse potential for Arena's weight-loss pill.

Vivus Piles New Debt On Top Of Excuses (Updated)

Vivus Piles New Debt On Top Of Excuses (Updated)

The $110 million loan suggests Vivus is still having trouble selling its weight loss pill.

TheStreet Quant Rating: D (Sell)